What is the appropriate evaluation work‑up for suspected allergic bronchopulmonary aspergillosis (ABPA) in a patient with asthma or cystic fibrosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 13, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

ABPA Evaluation Work-Up

Begin the diagnostic evaluation by immediately ordering A. fumigatus-specific IgE; if ≥0.35 kUA·L⁻¹, proceed with serum total IgE measurement, and if ≥500 IU·mL⁻¹, complete the full diagnostic panel including A. fumigatus-specific IgG, peripheral blood eosinophil count, and thin-section chest CT. 1

Initial Screening Algorithm

The 2024 ISHAM-ABPA working group guidelines provide a clear stepwise approach 1:

Step 1: A. fumigatus-specific IgE

  • Order this first in any patient with asthma, cystic fibrosis, COPD, or bronchiectasis who has clinical suspicion
  • Clinical red flags include: expectoration of brownish mucus plugs, recurrent wheezing despite treatment, fleeting pulmonary infiltrates, or unexplained deterioration

Step 2: If A. fumigatus-specific IgE ≥0.35 kUA·L⁻¹

  • Measure serum total IgE immediately
  • This two-step approach prevents unnecessary testing in non-sensitized patients

Step 3: If serum total IgE ≥500 IU·mL⁻¹

  • Complete the full diagnostic battery (detailed below)

Complete Diagnostic Panel

Once both essential components are positive, obtain 1:

Laboratory Tests

  • A. fumigatus-specific IgG (using lateral flow assay or enzyme immunoassay)
    • Use population-specific cut-offs when available (≥27 mgA·L⁻¹ for India, ≥60 for Japan, ≥40 for UK)
    • Otherwise use manufacturer recommendations 1
  • Peripheral blood eosinophil count (≥500 cells·μL⁻¹ diagnostic threshold)
    • Historical values are acceptable 1
  • Sputum fungal culture (suggested but not mandatory for ABPA; mandatory for ABPM) 1

Imaging Studies

  • Thin-section chest CT (mandatory at baseline) 1
    • Look specifically for: bronchiectasis, mucus plugging, high-attenuation mucus (HAM)
    • HAM is pathognomonic—if present, confirms ABPA even without all other criteria 1
    • Also assess for fleeting opacities, finger-in-glove appearance, lung collapse
  • Chest radiograph may show fleeting opacities (high specificity for ABPA) 1

Pulmonary Function Tests

  • Obtain baseline spirometry to characterize disease severity and establish monitoring parameters 1

Diagnostic Criteria Application

ABPA diagnosis requires 1:

Essential Components (both mandatory):

  1. A. fumigatus-specific IgE ≥0.35 kUA·L⁻¹
  2. Serum total IgE ≥500 IU·mL⁻¹

Plus any TWO of the following:

  • Positive A. fumigatus-specific IgG
  • Blood eosinophil count ≥500 cells·μL⁻¹
  • Chest CT findings consistent with ABPA (bronchiectasis, mucus plugging, HAM) OR fleeting opacities on chest radiograph

Critical Caveats

Low total IgE exceptions 1:

  • Serum total IgE <500 IU·mL⁻¹ may be acceptable if all other criteria are fulfilled
  • This occurs with: prior glucocorticoid treatment, elderly patients, or constitutively low baseline IgE

Pathognomonic finding 1:

  • High-attenuation mucus on CT confirms ABPA diagnosis even if other criteria are incomplete

When to consider ABPM instead 1:

  • If A. fumigatus-specific IgE <0.35 kUA·L⁻¹ but clinical picture suggests allergic bronchopulmonary mycosis
  • Requires: repeated isolation of non-Aspergillus fungi (≥2 sputum cultures or 1 BAL), fungus-specific IgE, total IgE ≥500 IU·mL⁻¹, plus two additional criteria
  • Test for IgE against rAsp f1, f2, and f4—absence strongly supports ABPM over ABPA 1

Tests NOT Recommended

  • Serum galactomannan: Do not use for ABPA diagnosis 1
  • Routine bronchoscopy: Not recommended unless 1:
    • Diagnosis remains uncertain after full workup
    • Suspected ABPM with uninformative sputum cultures
    • Unexplained hemoptysis
    • Suspicion of concurrent mycobacterial infection before starting glucocorticoids

Alternative When Serology Unavailable

If Aspergillus-specific IgE testing is unavailable, a positive type 1 skin test to Aspergillus antigens is acceptable 1

This algorithmic approach ensures systematic evaluation while avoiding unnecessary testing, with the 2024 ISHAM guidelines representing the most current international consensus for ABPA diagnosis.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.